Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review
Current Oncology Reports · 2024
DOI: 10.1007/s11912-024-01615-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2024. Verfasst von Yuji Tanaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Shiga University of Medical Science, 520-2192/Seta Tsukinowa-Cho, Otsu, Shiga, Japan. yujit@belle.shiga-med…. Hauptthemen laut MEDLINE: Fertility Preservation, Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Grants in Aid for Scientific Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE OF REVIEW: Adolescent and young adult (AYA) breast cancer survivors face a significant risk of infertility due to the gonadotoxic effects of (neo)adjuvant therapy, which complicates their ability to conceive post-treatment. While (neo)adjuvant therapy primarily aims to improve recurrence-free and overall survival, fertility preservation strategies should also be considered for young patients. This narrative review explores recent advancements in fertility preservation techniques, such as oocyte, embryo, and ovarian tissue cryopreservation, and evaluates the feasibility of modifying breast cancer (neo)adjuvant therapy to preserve fertility without compromising survival outcomes. RECENT FINDINGS: Our review highlights that clinical trials with co-primary endpoints of oncological safety and fertility preservation are limited, and substituting standard treatment regimens solely for fertility preservation is currently not recommended. Nevertheless, new clinical studies have emerged that either exclude highly ovarian-toxic agents, such as cyclophosphamide, or omit adjuvant therapy altogether, even if fertility preservation is not their primary endpoint. Unfortunately, many of these trials have not evaluated ovarian toxicity. Notably, since 2020, major oncology organizations, including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) have advocated for the routine assessment of ovarian toxicity in all clinical trials. The review underscores the importance of incorporating ovarian toxicity as a standard endpoint in future trials involving premenopausal breast cancer patients to identify treatment regimens that can effectively balance fertility preservation with treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Shiga University of Medical Science, 520-2192/Seta Tsukinowa-Cho, Otsu, Shiga, Japan. yujit@belle.shiga-med.ac.jp.
- Department of Obstetrics and Gynaecology, Shiga University of Medical Science, 520-2192/Seta Tsukinowa-Cho, Otsu, Shiga, Japan.
Förderung
- Grants in Aid for Scientific Research
Zitieren
APA
Tanaka, Y., Amano, T., Nakamura, A., Takahashi, A., Takebayashi, A., Hanada, T., Tsuji, S., & Murakami, T. (2024). Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review. Current Oncology Reports. https://doi.org/10.1007/s11912-024-01615-5
Vancouver
Tanaka Y, Amano T, Nakamura A, Takahashi A, Takebayashi A, Hanada T, et al. Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review. Current Oncology Reports. 2024. doi:10.1007/s11912-024-01615-5
BibTeX
@article{Tanaka2024,
author = {Tanaka, Yuji and Amano, Tsukuru and Nakamura, Akiko and Takahashi, Akimasa and Takebayashi, Akie and Hanada, Tetsuro and Tsuji, Shunichiro and Murakami, Takashi},
title = {Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review},
journal = {Current Oncology Reports},
year = {2024},
doi = {10.1007/s11912-024-01615-5}
}
EUVIMED